Cancer Cell Biology

You have full text access to this OnlineOpen article

Synergistic inhibition of head and neck tumor growth by green tea (−)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor

  1. Xin Zhang1,†,
  2. Hongzheng Zhang1,†,
  3. Mourad Tighiouart1,
  4. John E. Lee1,
  5. Hyung J. Shin2,
  6. Fadlo R. Khuri1,
  7. Chung S. Yang3,
  8. Zhuo (Georgia) Chen1,
  9. Dong M. Shin1,‡,*

Article first published online: 10 JUN 2008

DOI: 10.1002/ijc.23585

Issue

International Journal of Cancer

International Journal of Cancer

Volume 123, Issue 5, pages 1005–1014, 1 September 2008

Additional Information

How to Cite

Zhang, X., Zhang, H., Tighiouart, M., Lee, J. E., Shin, H. J., Khuri, F. R., Yang, C. S., Chen, Z. and Shin, D. M. (2008), Synergistic inhibition of head and neck tumor growth by green tea (−)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor. Int. J. Cancer, 123: 1005–1014. doi: 10.1002/ijc.23585

Author Information

  1. 1

    Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

  2. 2

    Quest Diagnostics, Atlanta, GA

  3. 3

    Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ

  1. †

    The first two authors contributed equally to this work.

  2. ‡

    Fax: +404-778-5520.

*Winship Cancer Institute, Emory University, 1701 Uppergate Road, Building C, 3rd Floor, Atlanta, GA 30322, USA

Publication History

  1. Issue published online: 17 JUN 2008
  2. Article first published online: 10 JUN 2008
  3. Manuscript Accepted: 27 FEB 2008
  4. Manuscript Received: 8 JAN 2008

Funded by

  • National Cancer Institute. Grant Numbers: R01 CA112643, U01 CA101244
  • NCI Head and Neck SPORE. Grant Number: P50 CA128613
  • Georgia Cancer Coalition Distinguished Scholar Award

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1428K)

References

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.
    Direct Link:
  • 2
    Forastiere A,Koch W,Trotti A,Sidransky D. Head and neck cancer. N Engl J Med 2001; 345: 1890–900.
  • 3
    Chen Z,Zhang X,Li M,Wang Z,Wieand HS,Grandis JR,Shin DM. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10: 5930–9.
  • 4
    Shin DM,Ro JY,Hong WK,Hittelman WN. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54: 3153–9.
  • 5
    Raymond E,Faivre S,Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60 (Suppl 1): 15–23; discussion 41–2.
  • 6
    Rubin Grandis J,Melhem MF,Gooding WE,Day R,Holst VA,Wagener MM,Drenning SD,Tweardy DJ. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824–32.
  • 7
    Maurizi M,Almadori G,Ferrandina G,Distefano M,Romanini ME,Cadoni G,Benedetti-Panici P,Paludetti G,Scambia G,Mancuso S. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996; 74: 1253–7.
  • 8
    Herbst RS,Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2004; 6 (Suppl 1): S7–S19.
  • 9
    Ali S,El-Rayes BF,Sarkar FH,Philip PA. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 2005; 4: 1943–51.
  • 10
    Herbst RS. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 2003; 30: 34–46.
  • 11
    Zhang X,Chen ZG,Choe MS,Lin Y,Sun SY,Wieand HS,Shin HJ,Chen A,Khuri FR,Shin DM. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005; 11: 6261–9.
  • 12
    Lotan R,Xu XC,Lippman SM,Ro JY,Lee JS,Lee JJ,Hong WK. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J Med 1995; 332: 1405–10.
  • 13
    Seixas-Silva JA,Jr,Richards T,Khuri FR,Wieand HS,Kim E,Murphy B,Francisco M,Hong WK,Shin DM. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg 2005; 131: 304–7.
  • 14
    Shin DM,Khuri FR,Murphy B,Garden AS,Clayman G,Francisco M,Liu D,Glisson BS,Ginsberg L,Papadimitrakopoulou V,Myers J,Morrison W,Gillenwater A,Ang KK,Lippman SM,Goepfert H,Hong WK. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001; 19: 3010–7.
  • 15
    Shin DM,Xu XC,Lippman SM,Lee JJ,Lee JS,Batsakis JG,Ro JY,Martin JW,Hittelman WN,Lotan R,Hong WK. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 1997; 3: 875–80.
  • 16
    Papadimitrakopoulou VA,William WN,Jr.,Dannenberg AJ,Lippman SM,Lee JJ,Ondrey FG,Peterson DE,Feng L,Atwell A,El-Naggar AK,Nathan CA,Helman JI,Du B,Yueh B,Boyle JO. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008; 14: 2095–101.
  • 17
    Lambert JD,Lee MJ,Lu H,Meng X,Hong JJ,Seril DN,Sturgill MG,Yang CS. Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr 2003; 133: 4172–7.
  • 18
    Conney AH. Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the Seventh DeWitt S. Goodman Lecture. Cancer Res 2003; 63: 7005–31.
  • 19
    Park OJ,Surh YJ. Chemopreventive potential of epigallocatechin gallate and genistein: evidence from epidemiological and laboratory studies. Toxicol Lett 2004; 150: 43–56.
  • 20
    Roy AM,Baliga MS,Katiyar SK. Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol Cancer Ther 2005; 4: 81–90.
  • 21
    Hong J,Lu H,Meng X,Ryu JH,Hara Y,Yang CS. Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (−)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res 2002; 62: 7241–6.
  • 22
    Masuda M,Suzui M,Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001; 7: 4220–9.
  • 23
    Sah JF,Balasubramanian S,Eckert RL,Rorke EA. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem 2004; 279: 12755–62.
  • 24
    Shimizu M,Deguchi A,Lim JT,Moriwaki H,Kopelovich L,Weinstein IB. (−)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin Cancer Res 2005; 11: 2735–46.
  • 25
    Skehan P,Storeng R,Scudiero D,Monks A,McMahon J,Vistica D,Warren JT,Bokesch H,Kenney S,Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107–12.
  • 26
    Chou TC,Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.
  • 27
    Ciardiello F,Bianco R,Damiano V,De Lorenzo S,Pepe S,De Placido S,Fan Z,Mendelsohn J,Bianco AR,Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5: 909–16.
  • 28
    Chun KH,Lee HY,Hassan K,Khuri F,Hong WK,Lotan R. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res 2003; 63: 4796–800.
  • 29
    Akervall J,Guo X,Qian CN,Schoumans J,Leeser B,Kort E,Cole A,Resau J,Bradford C,Carey T,Wennerberg J,Anderson H, et al. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res 2004; 10: 8204–13.
  • 30
    Hou Z,Sang S,You H,Lee MJ,Hong J,Chin KV,Yang CS. Mechanism of action of (−)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res 2005; 65: 8049–56.
  • 31
    Thelemann A,Petti F,Griffin G,Iwata K,Hunt T,Settinari T,Fenyo D,Gibson N,Haley JD. Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 2005; 4: 356–76.
  • 32
    Carpenter G,Cohen S. 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J Cell Biol 1976; 71: 159–71.
  • 33
    Levkowitz G,Waterman H,Zamir E,Kam Z,Oved S,Langdon WY,Beguinot L,Geiger B,Yarden Y. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998; 12: 3663–74.
  • 34
    Thangapazham RL,Singh AK,Sharma A,Warren J,Gaddipati JP,Maheshwari RK. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 2007; 245: 232–41.
  • 35
    Khan N,Afaq F,Saleem M,Ahmad N,Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (−)-epigallocatechin-3-gallate. Cancer Res 2006; 66: 2500–5.
  • 36
    Thomson S,Buck E,Petti F,Griffin G,Brown E,Ramnarine N,Iwata KK,Gibson N,Haley JD. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005; 65: 9455–62.
  • 37
    Sutter AP,Hopfner M,Huether A,Maaser K,Scherubl H. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer 2006; 118: 1814–22.
    Direct Link:
  • 38
    Chinnaiyan P,Huang S,Vallabhaneni G,Armstrong E,Varambally S,Tomlins SA,Chinnaiyan AM,Harari PM. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65: 3328–35.
  • 39
    Ahmad N,Feyes DK,Nieminen AL,Agarwal R,Mukhtar H. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997; 89: 1881–6.
  • 40
    Huether A,Hopfner M,Sutter AP,Schuppan D,Scherubl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol 2005; 43: 661–9.
  • 41
    Liang YC,Lin-shiau SY,Chen CF,Lin JK. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (−)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 1997; 67: 55–65.
    Direct Link:
  • 42
    Grovdal LM,Stang E,Sorkin A,Madshus IH. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 2004; 300: 388–95.
  • 43
    Sebastian S,Settleman J,Reshkin SJ,Azzariti A,Bellizzi A,Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 2006; 1766: 120–39.
  • 44
    Mizuno H,Cho YY,Zhu F,Ma WY,Bode AM,Yang CS,Ho CT,Dong Z. Theaflavin-3, 3′-digallate induces epidermal growth factor receptor downregulation. Mol Carcinog 2006; 45: 204–12.
    Direct Link:
  • 45
    Adachi S,Nagao T,Ingolfsson HI,Maxfield FR,Andersen OS,Kopelovich L,Weinstein IB. The inhibitory effect of (−)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 2007; 67: 6493–501.
  • 46
    Scaltriti M,Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268–72.
  • 47
    Feng FY,Varambally S,Tomlins SA,Chun PY,Lopez CA,Li X,Davis MA,Chinnaiyan AM,Lawrence TS,Nyati MK. Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 2007; 26: 3431–9.
View Full Article (HTML) Get PDF (1428K)